2006
DOI: 10.1620/tjem.208.103
|View full text |Cite
|
Sign up to set email alerts
|

Accurate Diagnosis of a Homozygous G1138A Mutation in the Fibroblast Growth Factor Receptor 3 Gene Responsible for Achondroplasia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2007
2007
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(3 citation statements)
references
References 9 publications
0
3
0
Order By: Relevance
“…Achondroplasia was the first genetic disorder that was hypothesized to have a paternal age component. Sporadic cases of achondroplasia and other dominant genetic disorders have been associated with advanced paternal age, suggesting that these mutations occur preferentially during spermatogenesis [9,10]. Diagnosis of achondroplasia is based on clinical findings, radiographic features and genetic test results [11].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Achondroplasia was the first genetic disorder that was hypothesized to have a paternal age component. Sporadic cases of achondroplasia and other dominant genetic disorders have been associated with advanced paternal age, suggesting that these mutations occur preferentially during spermatogenesis [9,10]. Diagnosis of achondroplasia is based on clinical findings, radiographic features and genetic test results [11].…”
Section: Discussionmentioning
confidence: 99%
“…Additional FGFR3 mutations were subsequently detected in thanatophoric dysplasia, hypochondroplasia and other disorders whose clinical phenotypes resemble achondroplasia. More than 97% of achondroplasia have a G to A point mutation at nucleotide 1138 of the FGFR3 "c.1138G>A" while approximately 1% have a G to C point mutation at the same site "c.1138G>C" [4].…”
Section: Introductionmentioning
confidence: 99%
“…Both pathogenic variants, mapped on chromosome 4, result in the same glycine to arginine substitution in the FGFR3 protein (p.Gly380Arg) [3,[7][8][9][10][11]. These mutations activate the FGFR3 receptor in the inhibition of chondrocyte proliferation with subsequent growth restriction and impaired endochondral bone formation [12]. De novo mutations account for most cases (80%) [13], and homozygosity occurrence has been reported seldomly to be compatible with life [14,15].…”
Section: Introductionmentioning
confidence: 99%